Peptide Comparison
GHK-Cu vs GHK
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
GHK-Cu has stronger documented evidence (Cosmetic Clinical + Animal Studies) than GHK (Preclinical + Cosmetic) while both occupy the matrikine class. When clinical-evidence tier is the deciding factor, GHK-Cu is the safer pick. GHK may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| GHK-Cu | GHK | |
|---|---|---|
| Class | Matrikine copper-tripeptide | Matrikine tripeptide; signaling/reparative |
| Drug class | Tissue Repair | Tissue Repair |
| Mechanism | Copper chelation and delivery to receptors; modulates hundreds of genes; stimulates collagen/elastin/decorin synthesis | Modulates expression of hundreds of genes related to tissue repair; copper transport |
| Route | Topical / SC / Microneedling | Topical / SC |
| Half-life | Varies by formulation | Minutes (plasma) |
| Dosage (research) | Topical 0.05-2% (cosmetic standard); 1 mg SC daily (Seeds Vol 1 starting dose, range up to 3 mg/day per r/Peptides wiki); microneedling 0.1-0.5% | 1-5 mg daily topical/SC (research) |
| Evidence tier | Cosmetic Clinical + Animal Studies | Preclinical + Cosmetic |
| Research depth | 119 indexed | 163 indexed |
| Availability | Cosmetic / Research | Research |
| Reported risks | Injection site irritation; theoretical copper toxicity at high doses; limited systemic safety data | Less bioavailable than GHK-Cu; limited injectable human trials |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHK-Cu or GHK?
GHK-Cu has stronger documented evidence (Cosmetic Clinical + Animal Studies) than GHK (Preclinical + Cosmetic) while both occupy the matrikine class. When clinical-evidence tier is the deciding factor, GHK-Cu is the safer pick. GHK may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between GHK-Cu and GHK?
GHK-Cu is classed as Matrikine copper-tripeptide; GHK is classed as Matrikine tripeptide; signaling/reparative. Reported mechanism: GHK-Cu, Copper chelation and delivery to receptors; modulates hundreds of genes; stimulates collagen/elastin/decorin synthesis; GHK, Modulates expression of hundreds of genes related to tissue repair; copper transport. Reported half-life: GHK-Cu, Varies by formulation; GHK, Minutes (plasma). Routes in published studies: GHK-Cu, Topical / SC / Microneedling; GHK, Topical / SC.
Which has stronger evidence, GHK-Cu or GHK?
GHK-Cu has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHK-Cu is graded Cosmetic Clinical + Animal Studies, with 16 cited sources on its reference page and 119 indexed studies. GHK is graded Preclinical + Cosmetic, with 8 cited sources on its reference page and 163 indexed studies.
Which is more accessible, GHK-Cu or GHK?
Neither GHK-Cu nor GHK is an FDA-approved drug. Catalog status: GHK-Cu, Cosmetic / Research; GHK, Research. GHK-Cu's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are GHK-Cu and GHK ever combined?
GHK-Cu and GHK appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…